15.01.2016 • News

KBR Buys Chematur Engineering Subsidiaries

KBR, a global engineering contractor based at Houston, Texas, USA and specialized in hydrocarbons, has paid $24.5 million to acquire three subsidiaries of Sweden’s Chematur Technologies – Weatherly, Plinke and Chematur Ecoplanning.

Weatherly, headquartered at Atlanta, Georgia, USA, provides proprietary nitric acid and ammonium nitrate technologies and services to the global fertilizer market. It has an installed base of 80 nitric acid plants worldwide with around a 30% market share of installed plants.

Bad Homburg, Germany-based Plinke, specializes in proprietary technology and equipment for the purification and concentration of inorganic acids used or produced in hydrocarbon processing facilities.

The third company, Chematur Ecoplanning, of Pori, Finland, offers proprietary evaporation and crystallization technologies and specialist equipment for weak acid and base solutions.

“Through these acquisition, KBR can more fully serve our clients’ fertilizer complex solution requirements, as well as expanding our consulting and technical services to improve plant performance throughout the plant’s lifecycle, said CEO Stuart Bradie.

Bradie said KBR’s ammonia and Weatherly’s fertilizer capabilities result in a powerful combination of industry-leading technologies, and Plinke and Ecoplanning enhance the scope of its technology solutions across expanded platforms. He added that the company sees great opportunities to extend the technologies outside North America to new customers and in revamping units for existing clients worldwide.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read